The recent FLOW trial, focusing on individuals with type 2 diabetes and chronic kidney disease, suggests that GLP-1 RAs can slow CKD progression 28
This is not endorsed by the NHS or NICE
From Obesity to Metabolic Health: Why Retatrutide Is a Game-Changer Abstract Obesity and type 2 diabetes have become global health crises, fueling complications such as cardiovascular disease, fatty liver disease, and metabolic syndrome
When used alongside a structured strength program, a weighted vest can add progressive overload for functional movements
Is semaglutide or tirzepatide better for Hashimoto's patients
If decision-makers do not understand obesity to be a long-term chronic disease, thats when we see these exclusionary policies or these very, very cumbersome utilization management practices that really just set up one barrier after another to prevent people from getting the care that they need